CD274 and neoplasm: Initial work by Orecchioni [48] and colleagues demonstrated in mouse models of B cell lymphoma that the combination of two chemotherapeutic agents—vinorelbine and cyclophosphamide—with anti-PD-L1 therapy reduced monocytic M-MDSCs and tumor burden.